Cincor to be Acquired by AstraZeneca
- Posted by ISPE Boston
- On January 13, 2023
Waltham-based, clinical-stage biopharm CinCor is slated to be acquired by British pharmaceutical giant AstraZeneca. Founded in 2018, CinCor’s mission is to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat, is in clinical development for the treatment of hypertension. Under the terms of the merger agreement, AstraZeneca will acquire all of […]
Read More